Contact Us

Antitope Ltd
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom

Telephone: +44(0) 1223 496190
Fax: +44(0) 1223 496191
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

PolyTherics Ltd
The London Bioscience Innovation Centre
2 Royal College Street
London NW1 0NH
United Kingdom

Telephone: +44 (0)20 7691 4927
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Latest News

 
10.03.2014
Antitope Strengthens Patent Estate Covering Core Technology for Humanisation/Deimmunisation of Antibodies and Proteins
Cambridge UK, 10 March 2014 - Antitope Ltd (“Antitope”), a PolyTherics company, today announces that the core patent covering its Composite Human Antibody™ and Composite Protein™ technologies has been granted in Japan (JP5461643). The grant of this patent strengthens...
30.07.2013
Antitope Announces Research Agreement with ChemomAb for Generation of Composite Human Antibodies against Inflammatory Diseases
Antitope Announces Research Agreement with ChemomAb for Generation of Composite Human Antibodies against Inflammatory Diseases Cambridge UK, 30 July 2013 – Antitope Ltd (“Antitope”), a PolyTherics company, today announced a research agreement with ChemomAb Ltd of Tel Aviv, Israel...
26.07.2013
PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals PolyTherics receives new investment to accelerate growth London, UK, Cambridge, UK, 26 July 2013 – PolyTherics Limited (“PolyTherics”) announces that it...
22.04.2013
Antitope Ltd., Announces Protein Deimmunisation Research Agreement with Research Corporation Technologies, Inc.
Cambridge, UK, 22nd April 2012 - Antitope Ltd, UK ("Antitope") today announced a Research Agreement with Research Corporation Technologies Inc., USA ("RCT") to re-engineer a toxic protein warhead for the next generation of antibody drug conjugates (ADCs) using it's proprietary...
06.02.2013
Antitope Ltd. and Eden Biodesign Ltd. enter into a Research Agreement
Cambridge UK, February 2013 - Antitope Ltd. (UK) today announced a Research Agreement with Eden Biodesign Ltd. (Liverpool, UK) for the development of therapeutic antibodies. As part of the Agreement, Antitope will apply its proprietary technologies towards the generation of a high yielding...
31.01.2013
Antitope and Rottapharm|Madaus Complete Successful Immunogenicity Assessment Research Collaboration
Cambridge UK, January 2013 - Antitope Ltd., UK ("Antitope") today announced the completion of a research collaboration with Rottapharma Biotech Srl, the Antibody Research Unit of the Italian healthcare company Rottapharm|Madaus, whereby Antitope applied is proprietary EpiScreenTM and in...
24.01.2013
Antitope Ltd., Announces Protein Deimmunisation Research Agreement with NeuroPhage Pharmaceuticals, Inc.
Cambridge UK, January 2013 - Antitope Ltd., UK ("Antitope") today announced a Research Agreement with NeuroPhage Pharmaceuticals, Inc., USA ("NeuroPhage") for the generation of a therapeutic protein with reduced immunogenicity. Under the Agreement, Antitope will apply it's...
24.01.2013
Meet Antitope at BIO-Europe Spring (Barcelona 11th-13th March)
Antitope will be participating in the Business Partnering Forum at the BIO-Europe and welcome the opportunity to discuss potential collaborations with companies that are interested in assessing and/or removing immunogenicity from protein therapeutics. Meetings can be arranged through the Conference...